增强心脏移植:利用带有气体的纳米载体来缓解感冒/缺氧压力
Chiara Rubeo1, Gjylije Hoti2, Magalì Giordano1
1Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Orbassano, Italy.
International journal of molecular sciences
|June 19, 2024
概括
装有气体的纳米载体,特别是纳米分子,通过减少感冒/缺氧-氧化损伤,显示出改善移植后早期心脏功能的潜力. 对于临床使用,需要进一步的研究.
科学领域:
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
- 心血管外科心血管外科
背景情况:
- 心脏移植 (HTx) 的结果可能受到缺血-再输液 (I/R) 损伤的限制.
- 装有气体的纳米载体 (G-LN) 在实验室中已经证明了对低氧/低氧化 (H/R) 的细胞保护作用.
- 优化保存解决方案对于在静态冷藏 (SCS) 期间减轻I / R损伤至关重要.
研究的目的:
- 评估不同G-LN变异在模拟HTx期间保持心脏功能方面的有效性.
- 评估G-LN对移植后生理-血液动力学参数和分子标记物的影响.
- 确定G-LN在心脏移植中减少冷/H/R诱导的麻醉的潜力.
主要方法:
- 维斯塔鼠心经历了4个小时的SCS与四个G-LN变体:O2-或N2-循环-尼格罗西尔-尼格罗斯-纳米单体 (CNN) 和O2-或N2-循环-尼格罗西尔-尼格罗斯-纳米海绵 (CNN-NS).
- 在反注射过程中监测生理-血液动力学参数 (例如,LVDP,RPP).
- 分析了与细胞损伤,氧化还原状态,亡和自相关的分子标志物.
主要成果:
- 与对照组相比,用CNN变体 (N2-CNN,O2-CNN) 治疗的心脏表现出左心室发育压力 (LVDP) 的改善以及速度压力产物 (RPP) 的更快恢复的趋势.
- 纳米海绵 (CNN-NS变体) 并没有提供类似的功能改进.
- 分子分析显示O2-CNN中的Beclin 1和N2-CNN中的p22phox增加,表明自和氧化还原环境发生了变化,这可能解释了晚期功能衰退.
结论:
- 纳米分子在提升早期心脏表现和缓解冷藏和再注射后的麻醉方面表现有前途,HTx.
- 在这项研究中,纳米海绵没有显示出类似的保护作用.
- 虽然早期的改善令人鼓舞,但为了在心脏移植中成功进行临床转换,需要进一步优化G-LN.
更多相关视频
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
711
09:47Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats
Published on: June 14, 2024
553
相关概念视频
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...